Centauri Therapeutics Ltd. has extended its series A financing round to £30 million (US$40.5 million) with the addition of a new £6 million (US$8 million) investment. Centauri initially closed its £24 million (US$32 million) series A round in 2022.
Almirall SA has nominated LAD-116 as a novel therapy targeting non-melanoma skin cancer for further development in IND-enabling studies. LAD-116 is based on collaborator Etherna Immunotherapies NV’s intratumoral mRNA/lipid nanoparticle (LNP) platform.
CD137 is a potent immune costimulatory receptor that promotes T-cell activation and enhances antitumor immune responses. However, systemic activation of CD137 can result in excessive immune stimulation and associated safety risks, such as hepatotoxicity, limiting its clinical use.
Brise Pharmaceutical (Shanghai) Co. Ltd. has discovered carbocyclic or heterocyclic derivatives acting as transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonists.
Apmonia Therapeutics SAS, the Centre National de la Recherche Scientifique and the Université de Reims Champagne Ardenne have disclosed LRP1-derived polypeptides acting as cathepsin D (CTSD) inhibitors.
Work at Emcure Pharmaceuticals Ltd. and Peptris Technologies has led to the identification of new fused bicyclic heterocyclic derivatives acting as histone deacetylase (HDAC) inhibitors.
In a recent study, researchers from Stony Brook University Renaissance School of Medicine and Cold Spring Harbor Laboratory investigated whether in vivo targeting of gastrointestinal tissues via foodborne delivery of Lm-based cancer vaccines could control tumor growth in murine models of colorectal cancer.
A new study by researchers at Stanford University and collaborating institutions aimed to investigate the safety and efficiency of lipid nanoparticle-mediated Cas13d mRNA delivery to uveal melanoma cells.
RSS
